On March 12, 2026, Enodia Therapeutics (Enodia), a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory and commercialization milestones, for a potential total of up to $127 million. Enodia has also agreed to pay tiered royalties on net sales. Wilson Sonsini Goodrich & Rosati advised Enodia on the transaction.

The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones.

The Wilson Sonsini team that advised Enodia on the transaction includes Seth Flaum, Aleksandar Vitomirov, and Greg Broome.

For more information, please see Enodia’s news release. Additional coverage can be found on Fierce Biotech.